Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Anti-N-Methyl-D-Aspartate Receptor Encephalitis × ofatumumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 6 Neoplasms 3 Leukemia, B-Cell 3 Recurrence 2 Lymphoma, Non-Hodgkin 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, Follicular 1 Lymphoma 1 Leukemia 1 Bronchiolitis Obliterans Syndrome 1 Autoimmune Diseases of the Nervous System 1 Anti-N-Methyl-D-Aspartate Receptor Encephalitis 1

Interventions

ofatumumab 1 daratumumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06867991 2025-07-15

RADIA

The First People's Hospital of Changzhou

Phase 3 Recruiting

Autoimmune Diseases of the Nervous System, Anti-N-Methyl-D-Aspartate Receptor Encephalitis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡